查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1970932

贪食症治疗市场－全球产业规模、份额、趋势、机会、预测：按类型、通路、地区和竞争格局划分，2021-2031年

Binge eating Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球神经性贪食症治疗市场预计将从 2025 年的 7.0815 亿美元成长到 2031 年的 10.7532 亿美元，复合年增长率为 7.21%。

该市场涵盖一系列药物疗法和实证心理疗法，旨在减少强迫性进食发作并治疗相关的心理疾病。主要成长要素包括全球饮食障碍盛行率的上升以及由于意识提升而导致的诊断率增加。此外，中枢神经系统兴奋剂的监管核准不断扩大治疗选择。正如饮食障碍联盟在2024年指出的那样，神经性贪食症是美国成年人中最常见的饮食障碍，其患病人数是神经性厌食症和心因性暴食症总和的三倍。

市场概览
预测期 2027-2031
市场规模：2025年 7.0815亿美元
市场规模：2031年 1,075,320,000 美元
复合年增长率：2026-2031年 7.21%
成长最快的细分市场 抗忧郁剂
最大的市场 北美洲

儘管有这些正面迹象，但由于专业治疗费用高昂且医疗覆盖范围有限，患者在就医方面仍面临许多障碍。在精神卫生基础设施资金不足的发展中地区，这种经济负担尤其沉重，导致潜在患者数量与实际获得有效治疗的患者数量之间存在巨大差距。因此，缺乏价格合理的治疗方案可能会严重限制製造商的获利能力，尤其是在对价格敏感的国际市场上。

市场驱动因素

市场成长的主要驱动力是强大的临床研发管线和药物开发活动，其特点是研发方向正从传统兴奋剂转向新型作用机制。製药公司正积极推进后期临床试验，以缓解FDA核准治疗方法的短缺，并在该领域投入大量资金。例如，Axsome Therapeutics在2024年4月的新闻稿中宣布启动ENGAGE III期临床试验，以评估多巴胺-去甲肾上腺素再回收抑制剂souliamfetol对成人神经性贪食症患者的疗效。这种临床活动的成长也延伸至迷幻剂辅助疗法等替代疗法。 Tryptamine Therapeutics在2024年11月的临床进展报告中宣布，其静脉注射菇素製剂TRP-8803的Ib期临床试验已完成受试者给药。

政府措施和优惠的报销政策在改善市场准入和确立治疗的医疗需求方面发挥着同等重要的作用。立法机构正日益加强拨款力度，以弥合诊断与有效治疗之间的差距，尤其是在医疗服务体係不完善、早期发现至关重要的基层医疗机构。联邦预算中用于培训医疗服务提供者和改善基础设施的资金也反映了这项努力。根据饮食饮食障碍联盟于2024年4月发布的《2024财年资金方案》报告，该组织获得了100万美元的资金，用于为基层医疗服务提供者提供筛检、简短干预和治疗转诊（SBIRT）方面的培训。这些政策成果不仅有助于减少社会歧视，还能鼓励医疗体系采用专门的暴食症（饮食障碍）治疗方案，并为全球医疗服务提供者拓展商业性发展机会。

市场挑战

高昂的专科治疗费用和不足的保险报销是全球神经性贪食症治疗市场成长的主要障碍。这些经济壁垒限制了患者获得必要的药物和心理治疗，导致市场规模萎缩。当患者面临过高的自付费用，且保险计划缺乏对长期管理的全面保障时，高诊断率往往无法转化为实际治疗病例。这种缺口严重限制了製药公司和医疗服务提供者的产生收入，尤其是在公共医疗资金不足以弥补资金缺口的地区。

这种经济负担规模庞大。根据蝴蝶基金会2024年的报告，澳洲饮食障碍造成的经济和社会总成本估计为669亿澳元，平均每人成本约为60,654澳元。如此高的个人成本凸显了经济危机，许多确诊患者无力负担持续治疗费用。因此，这些经济障碍阻碍了市场利用诊断趋势的能力，抑制了已开发国家和对价格敏感的国际地区的成长。

市场趋势

数位疗法和行动医疗应用的融合正在从根本上改变市场格局，消除地理和物流方面的障碍，从而实现有效治疗。虚拟优先的医疗模式获得了广泛的支持和投资者的信任，推动了远距和可扩展干预措施的普及，这些措施是对传统神经性贪食症治疗的补充。这种数位化变革使医疗服务提供者能够触及服务不足的群体，并将循证治疗直接送到患者家中，同时避免实体医疗机构人员配备的限制。作为这一趋势的象征，《行为健康商业》杂誌在2025年8月报道称，虚拟医疗服务提供商Equip Health筹集了约4700万美元的新股权融资，以满足日益增长的、便捷的、技术辅助的远距远端医疗需求。

同时，专业治疗中心市场正在进行策略整合，领先的行为健康医疗网络正在优化其业务组合，专注于临床品质和营运效率。在这种竞争激烈的环境中，整合型营业单位优先考虑严格的资料收集，以证明治疗效果，从而获得支付方的报销，并与分散的竞争对手区分开来。大型医疗机构正积极利用全网治疗结果数据来检验住院和门诊治疗通讯协定的有效性。例如，根据 Odyssey Behavioral Healthcare 于 2025 年 10 月发布的《2024 年治疗结果报告》，参与其饮食障碍住院计画的成年患者的症状总体减轻了 51%，这充分体现了此类专业整合系统所提供的临床价值。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球暴食症治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（抗忧郁症、抗惊厥药、兴奋剂、其他）
    • 分销通路（线下、线上）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美贪食症治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲神经性贪食症治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区贪食症治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲神经性贪食症治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲神经性贪食症治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球神经性贪食症治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Viatris Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Omeros Corp.
  • Pyramid Healthcare Inc.
  • Sumitomo Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Co
  • Tonix Pharmaceuticals Holding Corp.
  • Tryp Therapeutics Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 21708

The Global Binge Eating Disorder Treatment Market is projected to expand from USD 708.15 million in 2025 to USD 1075.32 million by 2031, reflecting a CAGR of 7.21%. This market encompasses a range of pharmacotherapeutic agents and evidence-based psychotherapies aimed at reducing compulsive overeating episodes and treating associated psychological conditions. Key growth drivers include the rising global prevalence of eating disorders and higher diagnosis rates resulting from enhanced mental health awareness. Additionally, regulatory approvals for central nervous system stimulants continue to widen therapeutic options. As noted by the Alliance for Eating Disorders in 2024, Binge Eating Disorder is the most prevalent eating disorder among U.S. adults, affecting three times as many individuals as Anorexia Nervosa and Bulimia Nervosa combined.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 708.15 MIllion
Market Size 2031USD 1075.32 MIllion
CAGR 2026-20317.21%
Fastest Growing SegmentAntidepressants
Largest MarketNorth America

Despite these positive indicators, the market confronts major obstacles due to the high costs associated with specialized treatment and insufficient insurance coverage, which limits patient access. This financial strain is particularly severe in developing regions where mental health infrastructure lacks adequate funding, creating a significant disparity between the number of potential patients and those receiving effective care. Consequently, the scarcity of affordable therapeutic alternatives could seriously restrict revenue potential for manufacturers, especially within price-sensitive international markets.

Market Driver

A primary engine for market growth is the robust clinical pipeline and drug development activity, marked by a transition toward novel mechanisms of action that go beyond traditional stimulants. Pharmaceutical firms are aggressively pushing late-stage trials to mitigate the shortage of FDA-approved therapies, drawing substantial investment into the sector. For instance, Axsome Therapeutics announced in a corporate press release in April 2024 the launch of the ENGAGE Phase 3 trial to assess solriamfetol, a dopamine and norepinephrine reuptake inhibitor, for treating adults with Binge Eating Disorder. This increase in clinical activity also encompasses alternative therapeutic classes, such as psychedelic-assisted treatments; Tryptamine Therapeutics reported in a November 2024 clinical update that it had completed subject dosing in a Phase 1b trial for TRP-8803, an IV-infused psilocin formulation.

Government initiatives and favorable reimbursement policies play an equally vital role in enhancing market accessibility and affirming the medical necessity of treatment. Legislators are increasingly designating funds to close the gap between diagnosis and effective care, particularly within underserved primary care environments where early detection is essential. This commitment is reflected in federal budgets aimed at improving provider training and infrastructure. According to an April 2024 report by the Eating Disorders Coalition regarding the Fiscal Year 2024 Funding Package, the organization secured $1 million specifically to train primary healthcare providers in screening, brief intervention, and referral to treatment (SBIRT). These policy achievements not only reduce stigma but also encourage healthcare systems to adopt specialized BED therapies, expanding the commercial reach for providers worldwide.

Market Challenge

The high expense of specialized care combined with insufficient insurance reimbursement represents a major hurdle to the growth of the Global Binge Eating Disorder Treatment Market. This economic barrier limits patient access to essential pharmacotherapeutic agents and psychotherapies, effectively shrinking the addressable market size. When patients encounter prohibitive out-of-pocket costs and insurance plans lack comprehensive coverage for long-term management, high diagnostic rates fail to convert into treated cases. This gap severely restricts revenue generation for pharmaceutical manufacturers and healthcare providers, particularly in areas where public health funding cannot cover the financial shortfall.

The scale of this financial burden is significant. As reported by the Butterfly Foundation in 2024, the total economic and social cost of eating disorders in Australia was estimated at $66.9 billion, with per-person costs averaging approximately $60,654. Such high individual expenses underscore an affordability crisis that precludes a large portion of the diagnosed population from obtaining consistent care. As a result, these financial obstacles hinder the market's capacity to leverage rising diagnostic trends, thereby stalling growth in both developed nations and price-sensitive international regions.

Market Trends

The integration of digital therapeutics and mobile health applications is fundamentally transforming the market by removing geographical and logistical obstacles to effective care. Virtual-first care models are securing significant traction and investor confidence, supporting a shift toward remote, scalable interventions that augment traditional Binge Eating Disorder therapy. This digital evolution enables providers to access underserved populations and administer evidence-based treatments directly to patients' homes, circumventing the capacity limits of physical facilities. Highlighting this trend, Behavioral Health Business reported in August 2025 that virtual provider Equip Health raised nearly $47 million in new equity funding to meet the growing demand for accessible, technology-enabled remote care.

Simultaneously, the market is experiencing a strategic consolidation of specialized treatment centers as major behavioral health networks refine their portfolios to focus on clinical quality and operational efficiency. In this competitive environment, consolidated entities are emphasizing rigorous data collection to prove treatment efficacy, thereby securing payer reimbursement and distinguishing their care models from fragmented competitors. Large-scale providers are increasingly utilizing network-wide outcome data to validate their residential and outpatient protocols. For example, Odyssey Behavioral Healthcare's October 2025 '2024 Treatment Outcomes Report' indicated that adults in their residential eating disorder programs achieved a 51% overall reduction in symptoms, demonstrating the clinical value delivered by these specialized, consolidated systems.

Key Market Players

  • Viatris Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Omeros Corp.
  • Pyramid Healthcare Inc.
  • Sumitomo Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Co
  • Tonix Pharmaceuticals Holding Corp.
  • Tryp Therapeutics Inc

Report Scope

In this report, the Global Binge eating Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Binge eating Disorder Treatment Market, By Type

  • Antidepressants
  • Anticonvulsants
  • Stimulants
  • Others

Binge eating Disorder Treatment Market, By Distribution Channel

  • Offline
  • Online

Binge eating Disorder Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Binge eating Disorder Treatment Market.

Available Customizations:

Global Binge eating Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Binge eating Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Antidepressants, Anticonvulsants, Stimulants, Others)
    • 5.2.2. By Distribution Channel (Offline, Online)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Binge eating Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Binge eating Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Binge eating Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Binge eating Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Binge eating Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Binge eating Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Binge eating Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Binge eating Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Binge eating Disorder Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Binge eating Disorder Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Binge eating Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Binge eating Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Binge eating Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Binge eating Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Binge eating Disorder Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Binge eating Disorder Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Binge eating Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Binge eating Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Binge eating Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Binge eating Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Binge eating Disorder Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Binge eating Disorder Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Binge eating Disorder Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Binge eating Disorder Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Binge eating Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Viatris Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson Services, Inc.
  • 15.3. Lupin Ltd.
  • 15.4. Omeros Corp.
  • 15.5. Pyramid Healthcare Inc.
  • 15.6. Sumitomo Pharma Co. Ltd.
  • 15.7. Takeda Pharmaceutical Co. Ltd.
  • 15.8. Eli Lilly and Co
  • 15.9. Tonix Pharmaceuticals Holding Corp.
  • 15.10. Tryp Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer